Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Expands By 5.1%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 684,800 shares, an increase of 5.1% from the May 15th total of 651,500 shares. Based on an average trading volume of 91,700 shares, the short-interest ratio is currently 7.5 days. Currently, 6.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors have recently modified their holdings of the business. Ieq Capital LLC purchased a new stake in shares of Jasper Therapeutics during the 4th quarter worth $43,000. Monaco Asset Management SAM purchased a new stake in shares of Jasper Therapeutics during the 4th quarter worth $197,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics during the 1st quarter worth $306,000. Fernwood Investment Management LLC lifted its position in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of Jasper Therapeutics during the 1st quarter worth $599,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on JSPR. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday. TD Cowen initiated coverage on Jasper Therapeutics in a research report on Monday, March 18th. They set an “outperform” rating on the stock. Royal Bank of Canada initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $80.00 price target on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Finally, Evercore ISI initiated coverage on shares of Jasper Therapeutics in a research note on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $64.29.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $23.19 on Thursday. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The firm has a 50 day moving average price of $23.57 and a 200 day moving average price of $18.62. The company has a market capitalization of $349.33 million, a PE ratio of -4.12 and a beta of 2.24.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.23. As a group, equities research analysts forecast that Jasper Therapeutics will post -4.36 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.